Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.
Article PubMed PubMed Central Google Scholar
Ishikawa Y, Miura T, Aoyagi T, Ogata H, Hamada S, Minami R. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2011;21:47–51.
Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2011;51:743–50.
Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, GFR CDtJEfE. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197–203.
Article PubMed CAS Google Scholar
Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 2009;40:438–42.
Article PubMed PubMed Central CAS Google Scholar
Kimura K, Morita H, Daimon M, Horio M, Kawata T, Nakao T, et al. Utility of cystatin C for estimating glomerular fltration rate in patients with muscular dystrophy. Int Heart J. 2016;57:386–8.
Article PubMed CAS Google Scholar
Braat E, Hoste L, De Waele L, Gheysens O, Vermeersch P, Goffin K, et al. Renal function in children and adolescents with Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25:381–7.
Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830–8.
Article PubMed CAS Google Scholar
Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta. 2000;300:83–95.
Article PubMed CAS Google Scholar
Matsumura T, Saito T, Fujimura H, Sakoda S. Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2012;52:211–7.
Motoki T, Shimizu-Motohashi Y, Komaki H, Mori-Yoshimura M, Oya Y, Takeshita E, et al. Treatable renal failure found in non-ambulatory Duchenne muscular dystrophy patients. Neuromuscul Disord. 2015;25:754–7.
Villa CR, Kaddourah A, Mathew J, Ryan TD, Wong BL, Goldstein SL, et al. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C. Neuromuscul Disord. 2016;26:637–42.
Motoki T, Shimizu-Motohashi Y, Saito I, Komaki H, Ishiyama A, Aibara K, et al. Renal dysfunction can occur in advanced-stage Duchenne muscular dystrophy. Muscle Nerve. 2020;61:192–7.
Article PubMed CAS Google Scholar
Kagen LJ, Moussavi S, Miller SL, Tsairis P. Serum myoglobin in muscular dystrophy. Muscle Nerve. 1980;3:221–6.
Article PubMed CAS Google Scholar
Adachi Y, Tamura R, Shindo T, Sasaki K, Masaki T, Nozu K, et al. A case of hereditary FSGS with Duchenne muscular dystrophy diagnosed in childhood. Jpn J Nephrol. 2021;63:831 (In Japanese).
Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347–61.
Article PubMed PubMed Central Google Scholar
Quinlivan R, Messer B, Murphy P, Astin R, Mukherjee R, Khan J, et al. Adult North Star Network (ANSN): consensus guideline for the standard of care of adults with Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:899–926.
Article PubMed PubMed Central CAS Google Scholar
Suehara M, Nagata A, Saito M, Kanzato N. 2cases of trying positive treatment to further complication after appearance of cardiopulmonary function failure In: Ministry of health and welfare editor. Reports of the clinical research team for the genetic counselling and the clinical research of the pathophysiology and treatment in muscular dystrophy patients. Kodaira: National Center of Neurology and Psychiatry; 1999. p. 430 (In Japanese)
Comments (0)